Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric severe plaque psoriasis trial of secukinumab versus placebo and etanercept
2014-005663-32Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in psoriasis and plaque psoriasis (3 arms), sponsored by Novartis. Primary endpoints: PASI 75 response and IGA mod 2011 0 or 1 response. Started Jun 2015; status: terminated.
02
Drugs
secukinumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2014-005663-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005663-32.